Action Karolinska Development Ab - 0P3C

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

6,50

Prix Achat

0,00

Prix Vente

0,00

Volume échangé

0,00

0,00 Fourchette du Jour 0,00

6,50 Plage de 52 semaines 6,50

Cap du marché

1,739B

Clôture Veille

6,50

Ouverture

Dernière Transaction

(O)

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

675

Actions en circulation

267 522 000

Rendement du Dividende

Ratio Cours sur Bénéfices

-214,52

Bénéfice par action (BPA)

-0,03

Chiffre d'affairess

1,84M

Bénéfice net

-8,1M

Secteur

Coml Physical, Biologcl Resh

Industrie

Coml Physical, Biologcl Resh

Site Web

www.karolinskadevelopment.com

Siège social

Solna, Swe

Fondé

Karolinska Development Ab est coté dans le secteur Coml Physical, Biologcl Resh de la London Stock Exchange avec le ticker 0P3C. Le dernier cours de clôture d'Karolinska Development Ab était de SEK6,50. Au cours de la dernière année, les actions de Karolinska Development Ab ont été négociées dans une fourchette de prix de SEK 6,50 à SEK 6,50.

Karolinska Development Ab compte actuellement 267 522 000 actions en circulation. La capitalisation boursière d'Karolinska Development Ab est de SEK1,74 milliard. Karolinska Development Ab a un ratio cours/bénéfice (ratio PE) de -214.52.

Karolinska Development’s portfolio company Umecrine Cognition appoints new CEO

Karolinska Development’s portfolio company Umecrine Cognition appoints new CEO STOCKHOLM, SWEDEN – April 1, 2025. Karolinska Development AB...

Karolinska Development’s portfolio company Umecrine Cognition presents promising preclinical Parkinson data at AD/PD 2025

Karolinska Development’s portfolio company Umecrine Cognition presents promising preclinical Parkinson data at AD/PD 2025 STOCKHOLM, SWEDEN –...

Karolinska Development Annual Report 2024 published

Karolinska Development Annual Report 2024 published STOCKHOLM, SWEDEN – March 21, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today...

Karolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study

Karolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study STOCKHOLM, SWEDEN – March 18...

Karolinska Development’s portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01

Karolinska Development’s portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01 STOCKHOLM, SWEDEN March 13...

Karolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial

Karolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial STOCKHOLM...

Karolinska Development’s portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01

Karolinska Development’s portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01 STOCKHOLM, SWEDEN...

Karolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface

Karolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface STOCKHOLM, SWEDEN...

Year-end Report - January-December 2024

Year-end Report - January-December 2024 STOCKHOLM – 14 February 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its...

Karolinska Development’s portfolio company Dilafor advances tafoxiparin following successful meetings with FDA and European regulatory authorities

Karolinska Development’s portfolio company Dilafor advances tafoxiparin following successful meetings with FDA and European regulatory authorities...

Période	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	6.5	6.5	6.5	0	0	DE
4	6.5	6.5	6.5	228	6.5	DE
12	6.5	6.5	6.5	675	6.5	DE
26	6.5	6.5	6.5	319	6.5	DE
52	6.5	6.5	6.5	301	6.5	DE
156	6.5	6.5	6.5	336	6.5	DE
260	6.5	6.5	6.5	657	6.5	DE

0P3C - Frequently Asked Questions (FAQ)

What is the current Karolinska Development Ab share price?

The current share price of Karolinska Development Ab is SEK 6,50

How many Karolinska Development Ab shares are in issue?

Karolinska Development Ab has 267 522 000 shares in issue

What is the market cap of Karolinska Development Ab?

The market capitalisation of Karolinska Development Ab is SEK 1,74B

What is the 1 year trading range for Karolinska Development Ab share price?

Karolinska Development Ab has traded in the range of SEK 6,50 to SEK 6,50 during the past year

What is the PE ratio of Karolinska Development Ab?

The price to earnings ratio of Karolinska Development Ab is -214,52

What is the cash to sales ratio of Karolinska Development Ab?

The cash to sales ratio of Karolinska Development Ab is 942,03

What is the reporting currency for Karolinska Development Ab?

Karolinska Development Ab reports financial results in SEK

What is the latest annual turnover for Karolinska Development Ab?

The latest annual turnover of Karolinska Development Ab is SEK 1,84M

What is the latest annual profit for Karolinska Development Ab?

The latest annual profit of Karolinska Development Ab is SEK -8,1M

What is the registered address of Karolinska Development Ab?

The registered address for Karolinska Development Ab is TOMTEBODAVAGEN 23 A, SOLNA, SE 171 65

What is the Karolinska Development Ab website address?

The website address for Karolinska Development Ab is www.karolinskadevelopment.com

Which industry sector does Karolinska Development Ab operate in?

Karolinska Development Ab operates in the COML PHYSICAL, BIOLOGCL RESH sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
CELCeladon Pharmaceuticals Plc	7,50p (150,00%)	634,63k
SCGLSealand Capital Galaxy Limited	1,175p (74,07%)	309,95M
ALGWAlpha Growth Plc	0,65p (36,84%)	8,88M
ORCPOracle Power Plc	0,021p (31,25%)	1,34B
AFPAfrican Pioneer Plc	1,10p (22,22%)	4,45M
ELEGElectric Guitar Plc	0,05p (-77,27%)	3,61M
PIERBrighton Pier Group Plc (the)	6,75p (-60,64%)	991,04k
CPAICapai Plc	0,305p (-23,75%)	437,82M
STGStrip Tinning Holdings Plc	24,00p (-22,58%)	139,27k
AFRNAferian Plc	2,50p (-16,67%)	67,67k
PREMPremier African Minerals Limited	0,031p (-3,13%)	2,38B
ORCPOracle Power Plc	0,021p (31,25%)	1,34B
BZTBezant Resources Plc	0,0265p (8,16%)	638,62M
SYMESupply@me Capital Plc	0,003p (0,00%)	458,13M
CPAICapai Plc	0,305p (-23,75%)	437,82M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Karolinska Development Ab (0P3C)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Karolinska Development Ab

0P3C Dernières nouvelles

Karolinska Development’s portfolio company Umecrine Cognition appoints new CEO

Karolinska Development’s portfolio company Umecrine Cognition presents promising preclinical Parkinson data at AD/PD 2025

Karolinska Development Annual Report 2024 published

Karolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study

Karolinska Development’s portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01

Karolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial

Karolinska Development’s portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01

Karolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface

Year-end Report - January-December 2024

Karolinska Development’s portfolio company Dilafor advances tafoxiparin following successful meetings with FDA and European regulatory authorities

Karolinska Development’s portfolio company Umecrine Cognition appoints new CEO

Karolinska Development’s portfolio company Umecrine Cognition presents promising preclinical Parkinson data at AD/PD 2025

Karolinska Development Annual Report 2024 published

Karolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study

Karolinska Development’s portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01

Karolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial

Karolinska Development’s portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01

Karolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface

0P3C - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	6.5	6.5	6.5	0	0	DE
4	6.5	6.5	6.5	228	6.5	DE
12	6.5	6.5	6.5	675	6.5	DE
26	6.5	6.5	6.5	319	6.5	DE
52	6.5	6.5	6.5	301	6.5	DE
156	6.5	6.5	6.5	336	6.5	DE
260	6.5	6.5	6.5	657	6.5	DE

Période	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	6.5	6.5	6.5	0	0	DE
4	6.5	6.5	6.5	228	6.5	DE
12	6.5	6.5	6.5	675	6.5	DE
26	6.5	6.5	6.5	319	6.5	DE
52	6.5	6.5	6.5	301	6.5	DE
156	6.5	6.5	6.5	336	6.5	DE
260	6.5	6.5	6.5	657	6.5	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Karolinska Development Ab (0P3C) Cours

Karolinska Development Ab (0P3C)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Karolinska Development Ab

0P3C Dernières nouvelles

Karolinska Development’s portfolio company Umecrine Cognition appoints new CEO

Karolinska Development’s portfolio company Umecrine Cognition presents promising preclinical Parkinson data at AD/PD 2025

Karolinska Development Annual Report 2024 published

Karolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study

Karolinska Development’s portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01

Karolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial

Karolinska Development’s portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01

Karolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface

Year-end Report - January-December 2024

Karolinska Development’s portfolio company Dilafor advances tafoxiparin following successful meetings with FDA and European regulatory authorities

Karolinska Development’s portfolio company Umecrine Cognition appoints new CEO

Karolinska Development’s portfolio company Umecrine Cognition presents promising preclinical Parkinson data at AD/PD 2025

Karolinska Development Annual Report 2024 published

Karolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study

Karolinska Development’s portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01

Karolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial

Karolinska Development’s portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01

Karolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface

0P3C - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	6.5	6.5	6.5	0	0	DE
4	6.5	6.5	6.5	228	6.5	DE
12	6.5	6.5	6.5	675	6.5	DE
26	6.5	6.5	6.5	319	6.5	DE
52	6.5	6.5	6.5	301	6.5	DE
156	6.5	6.5	6.5	336	6.5	DE
260	6.5	6.5	6.5	657	6.5	DE